Literature DB >> 9516076

Role of IGF-I in normal mammary development.

D L Kleinberg1.   

Abstract

Growth hormone (GH) is now believed to be the pituitary factor that is responsible for mammary ductal morphogenesis. Mammary development at puberty occurs because of synergy between GH and estrogen on formation of terminal end buds (TEBs). TEBs extend into the substance of the mammary gland fat pad, resulting in ductal morphogenesis. Ultimately, the whole mammary fat pad accommodates a complex network of ducts. IGF-I or des(1-3) IGF-I mimic the actions of GH on TEB formation in hypophysectomized, gonadectomized rats. Since GH stimulates IGF-I mRNA within the mammary gland synergistically, we hypothesize that IGF-I partially mediates actions of GH in mammary gland development. Studies in transgenic mice overexpressing IGF-I, des(1-3) IGF-I, or IGFBP-3 show that IGF-I causes ductal hypertrophy in the lactating mouse and prevention of post-lactational mammary gland involution. One of the mechanisms for this effect involves apoptosis. The potential role of GH or IGF-I in mammary carcinogenesis, and the applicability of animal studies to humans, are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516076     DOI: 10.1023/a:1005998832636

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

Review 1.  IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.

Authors:  D L Hadsell; S G Bonnette
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 2.  Regulation of mammary gland growth and morphogenesis by the mammary fat pad: a species comparison.

Authors:  R C Hovey; T B McFadden; R M Akers
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

3.  Elevated circulating IGF-I promotes mammary gland development and proliferation.

Authors:  Dara Cannata; Danielle Lann; Yingjie Wu; Sebastien Elis; Hui Sun; Shoshana Yakar; Deborah A Lazzarino; Teresa L Wood; Derek Leroith
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

4.  Prepubertal exposure to elevated manganese results in estradiol regulated mammary gland ductal differentiation and hyperplasia in female rats.

Authors:  Robert K Dearth; Jill K Hiney; Vinod K Srivastava; Alina M Hamilton; William L Dees
Journal:  Exp Biol Med (Maywood)       Date:  2014-05-20

Review 5.  Gynaecomastia--pathophysiology, diagnosis and treatment.

Authors:  Harmeet S Narula; Harold E Carlson
Journal:  Nat Rev Endocrinol       Date:  2014-08-12       Impact factor: 43.330

6.  Mammary adipocytes bioactivate 25-hydroxyvitamin D₃ and signal via vitamin D₃ receptor, modulating mammary epithelial cell growth.

Authors:  Stephen Ching; Soumya Kashinkunti; Matthew D Niehaus; Glendon M Zinser
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

7.  IGF-I stimulation of extracellular acidification is not linked to cell proliferation for autocrine cells.

Authors:  R M Robinson; R M Akers; K E Forsten
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

Review 8.  Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review.

Authors:  Harsh Patel; Victor Arruarana; Lucille Yao; Xiaojiang Cui; Edward Ray
Journal:  Endocrine       Date:  2020-02-17       Impact factor: 3.633

Review 9.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

10.  Plasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women.

Authors:  Adana A Llanos; Theodore M Brasky; Ramona G Dumitrescu; Catalin Marian; Kepher H Makambi; Bhaskar V S Kallakury; Scott L Spear; David J Perry; Rafael J Convit; Mary E Platek; Lucile L Adams-Campbell; Jo L Freudenheim; Peter G Shields
Journal:  Breast Cancer Res Treat       Date:  2013-03-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.